EVRY, France, September 14 /PRNewswire/ -- - Not for Distribution in the United States, Canada or Japan
Novagali Pharma, an emerging ophthalmic pharmaceutical company, announces that the update of its document de base was filed on September 12th , 2007 to the Autorité des marchés financiers (AMF).
This update concerns half-yearly IFRS accounts ended on June 30th, 2007. The document de base also announces that the product candidate Vekacia(R) was filed on July 27, 2007 with the European Agency for the Evaluation of Medicinal Product (EMEA), for marketing approval for the treatment of Vernal Keratoconjunctivitis ("VKC").
The document de base, registered on July 18, 2007 under number I.07-132 and its update are available free of charge from Novagali Pharma, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, 91000 Evry, France, on the AMF website ( http://www.amf-france.org) and on the Novagali Pharma website (http://www.novagali.com).
The public attention is drawn to the chapter 4 of the document de base, entitled << Risk Factors >>.
This press release, the information contained herein, the registration document and the actualization of the registration document which is referred to, do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Novagali Pharma in any country. No offer to sell shares in Novagali Pharma has been made, nor will be made, prior to the official approval by the Autorité des marchés financiers (AMF) of a prospectus comprising the registration document, its actualization which is the subject of this press release, and an offering prospectus which will be submitted to the AMF at a future date.
Shares of Novagali Pharma may not be sold in the United States of America (as defined under Regulation S of the U.S. Securities Act of 1933, as amended) without registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. There will be no registration of all or part of the offering referred to in this press release in the United States nor any public offering of Novagali Pharma securities in the United States. This press release may not be distributed, either directly or indirectly, in the United States and does not constitute an offer to sell securities in the United States.
There is no offer in the United Kingdom. In the United Kingdom, this information is directed only at investment professionals within the meaning of Article 19(1) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 of the United Kingdom (the Order) or persons who fall within Article 49(1) of the Order, or any other person to whom Novagali Pharma may legally transmit an invitation or solicitation to invest under the Order.
About Novagali Pharma : http://www.novagali.com
Novagali Pharma is an emerging ophthalmic pharmaceutical company based in the Génopôle biocluster in Evry (France), that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 8 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cationorm(R), a CE mark product for dry eye relief, and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, Novagali Pharma has raised a total amount of Euro 44 million in 3 series of financing.
Press contacts: Novagali Pharma, Geneviève Garrigos, +33-1-69-87-40-20, +33-6-65-54-60-19, genevieve.garrigos@novagali.com; Euro RSCG, Estelle Griffe, +33-1-58-47-95-25, +33-6-23-75-09-23, estelle.griffe@eurorscg.fr
__________________________________
FRANKFURT, Germany and SEOUL, Korea, September 14 /PRNewswire/ -- Reloaded Studios, a recently formed Korean game development company, today announce that they have entered into a licensing agreement with Crytek, the German developers of the highly anticipated upcoming release, Crysis, for use of the award winning CryENGINE 2 middleware to develop their new Action Strategy MMORPG.
"Our technology team carefully reviewed and analyzed both the features and limitations of all of the major game engines and middleware solutions which are currently available to license, before making our choice." says Ki-Yong Cho, Chief Executive Officer of Reloaded Studios. "No other engine came close to offering the dynamic features, developer friendly tools, or provided anything near the visual quality of the CryENGINE 2. We felt it was extremely important when our game is eventually released that it will still be able to stand apart from all other titles, either currently existing or presently in development, in what is now already a very competitive market. We felt only the CryENGINE 2 could support the dynamic content and massive landscapes we intend to build, let alone do justice to the unique art style we plan on bringing to our MMO. Licensing the CryENGINE 2 was an obvious and unanimous choice."
"We are really looking forward to working together with Reloaded Studios on this exciting new game development." said Faruk Yerli, managing director of Crytek, "The experienced team that Reloaded Studios has brought together will ensure they have the talent and resources to create a blockbuster hit with this title. When we saw the stunning concept visuals and exciting game design ideas they shared with us we immediately knew that what they have planned will be a true next-generation MMORPG, and become the kind of game which will set the visual and game play standards against which future MMO's will be judged."
About Crytek GmbH
Crytek GmbH ("Crytek") creators of the multiple award winning next- generation first person shooter Far Cry(R), and the soon to be released blockbuster hit Crysis(R), awarded as best PC Game of both E3 2007 and the 2007 Leipzig Games Convention, is an interactive entertainment development company with its headquarters located in Frankfurt Main, Germany and additional studios in Kiev, Ukraine and Budapest, Hungary. Crytek is dedicated to creating exceptionally high quality video games for the PC and next-generation consoles, powered by their proprietary cutting edge 3D-Game-Technology CryENGINE 2(R). For more information about Crytek, please visit http://www.crytek.com. Developers who are interested in obtaining a commercial license for the CryENGINE 2(R) middleware should mail their inquiries to cryengine@crytek.com
About Reloaded Studios, Inc.
Reloaded Studios, Inc. ("Reloaded Studios") was founded in Seoul, Korea in 2007 by one of the Korea's online game pioneers, Ki-Yong Cho, Co-Founder of Webzen (NASDAQ: WZEN) and Creator of the MMORPG "MU" which became a phenomenal success across Asia with more than 50 million subscribers; Chris Lee, former head of Worldwide Studio group who managed nine studios worldwide; and Jino Lee, former senior publishing producer for APB and Red 5 Studio's unnamed project and development producer for "Kingdom Under Fire: The Crusaders". The other key members of Reloaded Studios consist of MMO industry veterans with a tremendous amount of previous networked games experience between them. Reloaded Studios is currently developing innovative and challenging action next-generation MMO which will open up new markets. For more information about Reloaded Studios, please visit http://www.reloadedstudios.com.
Pressekontakt: Harald Seeley, Engine Business Manager, Crytek GmbH, Tel +49-69-219776669
__________________________________
ZOETERMEER, The Netherlands, September 14 /PRNewswire/ -- Tailor Made International Property B.V., the Dutch market leader in Carefree Living projects, is the proud recipient of awards in two categories at this year's International Property Awards. These prestigious awards were presented ed in London on 14 September 2007.
Now in their 13th year, the International Property Awards aim to distinguish the highest level of achievement in a range of property related fields. The organisation is part of the American CNBC network. Awards are presented per country in sixteen categories. Tailor Made, the organisation from Zoetermeer in the Netherlands, specialises in unique housing concepts for the over-50 target age group and has been short listed for two awards in the categories 'Best Estate Agent in the Netherlands' and 'Best Development in France'.
Tailor Made are honoured that the Internationals property awards recognitions Tailor Made as a professional real estate agency. The recognition of its development- in France underlines the success of Le Castèl as a housing project. Le Castèl is located in le Gers, in the Midi-Pyrenees. The quality of design and build and level the services and facilities provided is extremely high, (as they are in Carefree Living projects in four
other countries across Europe).
Le Castèl is being developed on the south flank of two hills near the village of Castelnau d'Auzan. Detached villas with private gardens and spacious apartments with balconies or terraces will be built on the plots. Le Castèl is conveniently situated between Bordeaux and Toulouse. Available to buy off-plan now, the project will be completed by end 2009.
Tailor Made is an pioneer in the field of Carefree Living projects driven by research on over 50's demographics, lifestyle, marketing and healthcare requirements. Carefree Living encapsulates a stress free life in a luxury home situated in a peaceful part of a favourite European country. Aimed at ensuring that the over 50's communities are given complete comfort and security within a state of the art residential environment, supported by a complete package of services and amenities. All properties are 'lifecycle proof' which means that any physical or logistical obstacles that could arise as individuals become older and less mobile are 'designed out'. Carefree Living also guarantees on site medical facilities with English speaking staff including a doctor.
For more information please contact: Veronica Newson, +44-(0)-7801-231312, vnewson@tailormadebv.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment